Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan With or Without Everolimus in LAR Subtype TNBC
NCT07760844Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2026
- Primary completion
- Sep 2028
01
Overview
Phase 3, randomised, open-label trial of trastuzumab rezetecan and everolimus in triple-negative breast cancer (TNBC) (2 arms), sponsored by Fudan University. Primary endpoint: Progression Free Survival at 24 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecaneverolimus
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07760844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07760844.